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Abstract Survivors of hereditary retinoblastoma have a
high risk of second primary malignancies, but it has
not been investigated whether speciﬁc RB1 germline
mutations are associated with greater risk of second pri-
mary malignancies in a large cohort. We conducted a ret-
rospective cohort study of 199 survivors of hereditary
retinoblastoma with a documented RB1 germline mutation
diagnosed between 1905 and 2005. In total, 44 hereditary
retinoblastoma survivors developed a second primary
malignancy after a median follow-up of 30.2 years (range
1.33–76.0). A signiﬁcantly increased risk of second pri-
mary malignancy was observed among carriers of one of
the 11 recurrent CGA[TGA nonsense RB1 mutations
(hazard ratio (HR) = 3.53; [95% conﬁdence interval
(CI) = 1.82–6.84]; P = .000), and there was a signiﬁ-
cantly lower risk for subjects with a low penetrance
mutation (HR = .19; [95% CI = .05–.81]; P = .025). Our
ﬁndings suggest a genotype-phenotype correlation for
second primary cancers of retinoblastoma survivors and
may impact on long-term surveillance protocols of patients
with hereditary retinoblastoma, if conﬁrmed by future
studies.
Keywords Retinoblastoma  RB1 gene  Second primary
malignancies  Germline mutation  Genotype-phenotype
correlation
Introduction
Retinoblastoma is the most common primary intraocular
malignancy of childhood [1]. Mutational inactivation of
both alleles of the RB1 tumor suppressor gene in the
developing retina initiates the formation of retinoblastoma
[2, 3]. The RB1 gene consists of 27 exons and is located on
chromosome 13q14 (GenBank accession number L11910,
MIM#180200). The gene encodes a ubiquitously expressed
nuclear protein, which is involved in cell cycle regulation,
cellular differentiation and survival [4]. About 40% of
retinoblastoma patients have a hereditary predisposition,
caused by a heterozygous germline mutation in the RB1
gene and are usually bilaterally affected [5]. Over 600
different pathogenic mutations have been described.
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DOI 10.1007/s10689-011-9505-3Patients with nonhereditary retinoblastoma only have one
eye affected, no germline mutation in the RB1 gene and
two somatic retinal RB1 mutations.
As is known from long-term follow-up studies [6–10],
hereditaryretinoblastoma subjectshave astronglyincreased
risk for second primary malignancies, (including osteosar-
coma,softtissuesarcoma,melanomaandepithelialcancers)
which is associated with excess mortality [11–13]. So far, it
has not been examined in a large cohort of retinoblastoma
patients whetherspeciﬁc RB1mutationsmightbeassociated
with greater risk of second malignancy.
The objective of the present study was to investigate the
RB1 genotype in relation to second malignancy risk in
hereditary retinoblastoma subjects.
Materials and methods
Patients
In the Netherlands we have data available of Dutch reti-
noblastoma subjects diagnosed from 1862 onwards.
Detailed information on data collection and follow-up has
been described previously [9]. Relevant data collected for
the present study were family history of retinoblastoma,
tumor laterality, treatment for retinoblastoma, reports on
invasive cancers, and date and (underlying) cause of death.
Only the ﬁrst cancer after retinoblastoma was included in
this study. Time at risk for a second primary cancer began
at diagnosis of retinoblastoma and ended on the date of
second malignancy diagnosis, emigration, the date last
known to be alive, the date of death, or the closing date of
the study, whichever came ﬁrst.
Patients with bilateral disease, a positive family history
of retinoblastoma, or a germline mutation in the RB1 gene
detected by chromosomal or DNA analysis were classiﬁed
as hereditary. The remaining patients, those with unilateral
retinoblastoma, no family history of retinoblastoma, and no
germline mutation detected in the RB1 gene, were classi-
ﬁed as having non-hereditary retinoblastoma.
Eligible subjects for the current study included all
hereditary retinoblastoma patients from the Dutch retino-
blastoma cohort (1862–2005), in whom a germline RB1
mutation was documented. If a retinoblastoma patient had
died before DNA-testing could be performed, but a RB1
mutation was determined in the family, the patient was
considered to be a carrier of the familial mutation
(n = 26). Every affected family member was handled as a
single case in the analysis. Of the 1,028 retinoblastoma
patients in the Dutch cohort, we identiﬁed a total of 410
(39.9%) hereditary cases. Two-hundred eleven patients
were excluded because no DNA analysis could be per-
formed (n = 180) or DNA analysis did not detect a RB1
mutation (n = 31). The remaining 199 patients were
included in this study (see Fig. 1), of whom 168 were alive
at the time of inclusion.
This study was approved by the Medical Ethics Com-
mittees of all participating hospitals, and was conducted in
accordance with the principles of the Helsinki declaration.
Mutation screening
Since the beginning of the 1990s all newly diagnosed ret-
inoblastoma patients in the Netherlands undergo germline
RB1 mutation analysis. Many patients who were diagnosed
before that time underwent DNA-testing between 1990 and
Fig. 1 Flow chart showing
reasons for inclusion and
exclusion of retinoblastoma
patients with hereditary
retinoblastoma from our cohort.
In the total group of 410
hereditary retinoblastoma
patients from our cohort, 99
primary tumors (SPT) have
been diagnosed. In the ﬂow
chart is also depicted in which
in- or excluded group these
SPT’s have occurred.
Percentage is calculated from
the total of 99 SPT’s
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1232005, when they were referred to the clinical genetics
department (n = 90). Rb patients diagnosed prior to 1990,
in whom mutation testing had not yet been performed at the
time of the study and who wanted to participate in the
study, were invited to undergo DNA-testing and were
offered genetic counseling (n = 23).
DNA analysis included direct sequencing of exons 1 and
15, and the RB1 promoter and Denaturing Gradient Gel
Electrophoresis (DGGE) analysis of the other exons and
ﬂanking intronic sequences. To detect large deletions and
duplications Multiplex Ligation-dependent Probe Ampliﬁ-
cation (MLPA) analysis was performed. If warranted, e.g.
when dysmorphic features or mental retardation was noted,
karyotyping was performed to detect chromosomal rear-
rangements. With these techniques we have been able to
detect 90% of mutations in familial and/or bilateral cases.
Type of RB1 mutation
In the RB1 gene are several methylated CGA codons
known to lead to 11 recurrent nonsense mutations by C[T
transitions [14–16]. An important factor in the high
recurrence of mutations at these sites was shown to be
deamination of 5-methylcytosine [17].
For this study mutations in the promoter, exon 1, mis-
sense mutations and deletions of the complete RB1 gene
were regarded as low penetrance mutations, based on
previous studies [18–21]. Four out of six familial splice
mutations were also regarded as low penetrance mutations,
based on a diseased eye ratio (DER) of B1.5, deﬁned as the
total number of affected eyes per family divided by the
number of mutation carriers in the family [22, 23]. To
exclude possible mosaicism as a cause of milder expression
the ﬁrst mutation carrier in these families was excluded
from the analysis.
Statistical methods
We compared the frequency of second primary cancers
among hereditary retinoblastoma survivors with speciﬁc
documented RB1 mutations, and tested for differences
using Chi-square tests.
Multivariate Cox regression analysis was performed to
quantify the effects of speciﬁc RB1 mutations on the risk of
second primary malignancies. Therapy, age, laterality, sex,
and familial or sporadic occurrence were taken into
account as possible confounders (SPSS, Chicago, IL).
Results
Median age of all patients included in the study cohort was
30.0 years (range 1.0–75.0). Of the total of 199 partici-
pants, 111 were familial cases and 88 concerned sporadic
patients. After a median follow-up time of 30.2 years
(range 1.33–76.0), 44 carriers of a RB1 mutation from 31
different families developed a second primary malignancy.
Table 1 shows the number of germline RB1 mutations
according to type of mutation and lists the number of
second primary tumors according to type of mutation. The
Table 1 Number and type of second primary tumor (SPT) by mutation type
Type of RB1 mutation
a Number
of carriers
n (%)
a
Number of cases
with SPT
n (%)
b
Type of SPT
Sarcoma
c Melanoma Epithelial cancer Other
d
Nonsense/frameshift mutation 117 (58.8) 31 (26.5) 11 8 10 2
Recurrent nonsense mutation 49 (41.9) 17 (34.7) 7 7 2 1
Low penetrance mutation = exon 1 7 (6) 1 (14.3)
Splice mutation 34 (17.1) 7 (20.6) 2 1 4 0
Low penetrance mutation 11 (32.4) 0
Large rearrangements 35 (17.6) 6 (17.1) 2 2 2 0
Low penetrance mutation 21 (60) 1 (4.8) 1
Missense mutation 11 (5.5) 0 0 0 0 0
Low penetrance mutation 11 (100) 0
Promoter mutation 2 (1) 0 0 0 0 0
Low penetrance mutation 2 (100) 0
Total 199 44 (22.1) 15 11 16 2
a Subclassiﬁcation of the mutation type is shown in italics, percentage as compared to total number of cases with this mutation type
b Percentage of cases with an SPT as compared to total number of cases with this mutation type
c Including soft tissue sarcoma, osteosarcoma, and chondrosarcoma
d Malignant tumor not otherwise speciﬁed and brain tumor
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123mutations found in patients who developed a second
malignancy were distributed throughout most of the RB1
gene and did not appear to cluster in one region (Fig. 2).
There was no correlation between the different types of
second malignancies diagnosed in these patients and the
type of mutation or the region of the gene where the
mutation was located. In the group of retinoblastoma sur-
vivors who developed a second malignancy, only nonsense
and frameshift mutations, certain splice mutations and
large rearrangements were observed.
Table 2 displays the mutations of all patients who
developed a second primary malignancy, along with clin-
ical details, listed according to subcategories of germline
RB1 mutation type.
We assessed the risk of second malignancy in relation to
type of mutation by multivariable Cox model analysis,
adjusted for age and therapy. This showed that subjects
carrying one of the recurrent nonsense mutations had a
signiﬁcantly elevated risk of developing second malig-
nancies, compared to subjects carrying other mutations
(hazard ratio [HR], 3.53; [95% conﬁdence interval (CI),
1.82–6.84]; P = .000). Since 5 members of family 8
developed a second malignancy, we did the same analysis
while excluding this family. This did not signiﬁcantly
change the outcome (HR, 3.17; [95% CI, 1.50–6.69];
P = .002). Leaving both family 8 and all low penetrance
mutations out of the analysis, showed a lower but still
statistically signiﬁcantly increased risk for recurrent non-
sense mutations as compared to other mutations (HR, 2.46;
[95% CI, 1.14–5.28]; P = .02).
Table 3 shows the recurrent nonsense mutations known
in the RB1 gene, and displays which of these mutations are
found in our cohort in relation to the number of patients
and the number of second primary cancers in these
patients.
A statistically signiﬁcantly decreased risk for a second
primary malignancy was found in the 52 patients with a
low penetrance mutation when compared to other muta-
tions (HR, .19; [95% CI, .05–.81]; P = .025). Of all 34
patients carrying a splice mutation, eleven were carrier of a
low penetrance mutation according to our deﬁnition, i.e. a
DER B1.5. None of the carriers of a low penetrance splice
mutation developed a second primary cancer. Out of 21
carriers of a deletion involving the whole RB1 gene, just
one developed a sarcoma and one out of seven carriers of a
mutation in exon 1 developed breast cancer at the age of
59. No second malignancies were observed in carriers of a
RB1 promoter or missense mutation (n = 13).
1   2 3 4 5 6 7 8 9 1 0  11 12 13 14 15 16 17 18 1 9  20 21 22 23 24 25 26 27
Whole gene deletion
Deletion exon 3-17
Deletion exon 6-17
Deletion exon 9-27
Deletion exon 10/11
Duplication exon 3
Fig. 2 Graphical representation of RB1 and mutations found among
hereditary retinoblastoma subjects diagnosed with a second primary
malignancy (n = 44). Exons 1 through 27 are not drawn to scale.
Every symbol represents a retinoblastoma subject diagnosed with a
second primary malignancy. Black symbols represent sporadic
hereditary retinoblastoma subjects. Greyscale coloured symbols
represent subjects with familial retinoblastoma. Downward-pointing
symbols represent mutations in exons, and upward-pointing symbols
represent mutations in introns. The horizontal lines below depict large
rearrangements
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Our study is the ﬁrst to examine the association between
speciﬁc RB1 germline mutations and the risk of second
primary malignancies in a nationwide well-documented
cohort. Adjusting for age and therapy, we found a higher
second primary malignancy risk for retinoblastoma sub-
jects carrying a recurrent nonsense mutation, and a lower
risk for carriers of a low penetrance mutation.
We ﬁrst compared the risk of second primary malig-
nancies for carriers of recurrent nonsense mutations to all
other mutations in the RB1 gene. Because one family (F8)
with many family members affected by a second malig-
nancy may have inﬂuenced the outcome too much, we
excluded this family from the analysis. This still showed a
statistically signiﬁcantly increased risk. It is remarkable
that 4 members of this family developed a melanoma. This
could be due to common genetic background, though this
phenomenon does not hold true for other families. As far as
we are aware, the family does not display any signs of
dysplastic nevus syndrome. We further hypothesized that
the increased risk of second malignancies for recurrent
mutations compared to all other mutations may have been
caused by a substantial contribution of the lower risk of
second malignancies for low penetrance mutations, inclu-
ded in the comparison. Therefore we also left the low
penetrance mutations out of the analysis. This still showed
a signiﬁcantly increased risk of second primary cancers for
recurrent nonsense mutations. Three recurrent nonsense
mutations did not demonstrate any second malignancies in
our study cohort (Table 3). Whether these mutations do not
lead to a higher second malignancy risk, needs to be
clariﬁed in future studies.
What could be the cause of the higher risk for second
malignancies in carriers of recurrent nonsense mutations?
Nonsense and frameshift mutations are associated with
bilateral retinoblastoma and high ([90%) penetrance [19],
irrespective of the location of the premature stop mutation.
This is attributed to nonsense mediated mRNA decay
(NMD): a mechanism of mRNA surveillance that prevents
the expression of truncated proteins, by breaking down
mutant mRNA containing a premature termination codon
[24]. NMD can be beneﬁcial, eliminating truncated tran-
scripts that could lead to proteins with possible dominant
negative or gain-of function effects, but may also be
harmful when preventing translation of truncated protein
that would otherwise still be partly functional [25, 26].
Studies have also shown that NMD efﬁcacy may vary
between tissues [27, 28]. An explanation for our ﬁndings
could be that speciﬁc nonsense mutations escape NMD in
certain tissues, which will result in the expression of a
truncated protein. This truncated protein may either have
residual activity resulting in a milder effect or may have a
dominant negative effect, as has been described for other
tumor-suppressor genes [25, 29]. The higher risk in
recurrent nonsense mutation carriers may then be explained
by a differential effect of NMD between these mutations
and other truncating mutations. How such a differential
effect would speciﬁcally exist between the two different
types of truncating mutations remains to be determined.
Alternatively, while the recurrent nonsense mutations
result in the loss of a 5-methylcytosine within the gene, this
may affect the chromatin structure and/or expression of the
gene and thereby increasing the chance of transformation.
However, in spite of a clearly elevated risk for recurrent
nonsense mutations in our cohort, we cannot rule out that
the elevated risk is a chance ﬁnding.
Genotype-phenotype correlations of RB1 mutations
have been described for speciﬁc types of mutations: certain
splice mutations, promoter, exon 1 and missense mutations
lead to reduced expressivity (unilateral retinoblastoma) and
incomplete penetrance (unaffected carriers) of retinoblas-
toma [18, 19, 21, 23, 30]. This is attributed to a reduction in
the amount of normal protein that is produced or to residual
activity of mutant protein [18, 19]. Reduced expressivity
and incomplete penetrance have also been described for
deletions of the complete RB1 gene. This is thought to be
caused by co-deletion of adjacent unknown genes leading
to a greater chance of apoptosis, when the wildtype allele is
lost as the second hit in the tumor [20]. In line with reduced
expressivity in the retina, we demonstrated a lower risk of
second primary cancers for carriers of these low penetrance
mutations. In our study group none of the carriers (n = 24)
of a missense, promoter or low penetrance splice RB1
mutation developed a second malignancy, and just one out
Table 3 List of the 11 recurrent RB1 nonsense mutations, the num-
ber of patients in our cohort carrying the mutation and the number of
patients with this mutation who developed a second primary tumor
(SPT)
Exon Mutation Protein Number of
patients in
our cohort
Number of
patients who
developed a SPT
8 g.59683C[T Arg.251X 2 0
8 g.59695C[T Arg.255X 1 1
10 g.64348C[T Arg.320X 5 2
11 g.65386C[T Arg.358X 3 1
14 g.76430C[T Arg.445X 11 5
14 g.76460C[T Arg.455X 8 0
15 g.76898C[T Arg.467X 1 1
17 g.78238C[T Arg.552X 3 2
17 g.78250C[T Arg.556X 5 0
18 g.150037C[T Arg.579X 7 3
23 g.162237C[T Arg.787X 3 2
Total 49 17
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123of 7 carriers with a mutation in exon 1 developed another
cancer, i.e. breast cancer at age 59. The latter may also be
attributed to the high population risk of breast cancer. A
lower risk for second primary malignancies was noted for
carriers of a complete deletion of the RB1 gene as well:
only one out of 21 carriers developed a second malignancy
(i.e. rhabdomyosarcoma at age 11).
Strength of our study is the unique large data set of
genotyped survivors of retinoblastoma from a population
based cohort. Very few studies on genotype-phenotype
relations of RB1 mutations mention second primary can-
cers. Two studies on mutations in de RB1 gene stated that
they could not detect an association between the mutation
and manifestation of a second primary cancer or tumor type
[21, 31]. These studies included only a few patients with
second primary cancers, however. Some limitations of our
study should be considered. First, our mutation detection
rate was 90% for all familial and bilateral cases at the time
of the study. Leaving 10% of hereditary patients out of the
analysis may have inﬂuenced the outcome. Some mutations
may have been missed, because they are present in a
mosaic state; others because they might be located deep in
an intron. Second, some types of mutations (e.g. promoter
mutations) are relatively rare and therefore some mutation
type subgroups were small, making it difﬁcult to draw ﬁrm
conclusions. A third limitation is that RB1 mutation
detection has become available just 20 years ago. Although
many patients from the Dutch retinoblastoma cohort have
been genotyped in the past years, this study still comprises
a relatively young group of retinoblastoma subjects; almost
50% of all known patients with hereditary retinoblastoma
could be included. Quite a few patients diagnosed with
(osteo)sarcoma had already died before it was possible to
perform DNA analysis. The exclusion of these (osteo)sar-
comas may have limited our ability to detect possible
associations between speciﬁc mutations and sarcoma risk.
In conclusion, our results suggest a genotype-phenotype
correlation for second primary malignancies of retino-
blastoma survivors and may impact on long-term surveil-
lance protocols of patients with hereditary retinoblastoma,
if conﬁrmed by future studies.
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